Last reviewed · How we verify
Cyclophosphamide and steroids — Competitive Intelligence Brief
phase 3
Alkylating agent + corticosteroid combination
Oncology, Immunology, Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Cyclophosphamide and steroids (Cyclophosphamide and steroids) — Radboud University Medical Center. Cyclophosphamide is an alkylating chemotherapy agent that damages DNA to kill rapidly dividing cells, while steroids suppress immune responses and reduce inflammation.
Comparator set (5 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cyclophosphamide and steroids TARGET | Cyclophosphamide and steroids | Radboud University Medical Center | phase 3 | Alkylating agent + corticosteroid combination | ||
| Cyclophosphamide and glucocorticoids | Cyclophosphamide and glucocorticoids | Peking Union Medical College Hospital | marketed | Alkylating agent + corticosteroid combination | ||
| Bus and Dex | Bus and Dex | The Cleveland Clinic | marketed | Alkylating agent + corticosteroid combination | ||
| Melphalan+Prednisolone | Melphalan+Prednisolone | Cigdem Sahinbas YILMAZ | phase 3 | Alkylating agent + Corticosteroid combination | DNA (melphalan); glucocorticoid receptor (prednisolone) | |
| Bortezomib, Melphalan, Prednisone | Bortezomib, Melphalan, Prednisone | Fondazione EMN Italy Onlus | phase 3 | Proteasome inhibitor + alkylating agent + corticosteroid combination | 20S proteasome (bortezomib); DNA (melphalan); glucocorticoid receptor (prednisone) | |
| Dexamethasone, Rituximab, Cyclophosphamide | Dexamethasone, Rituximab, Cyclophosphamide | University of Ulm | phase 3 | Monoclonal antibody + alkylating agent + corticosteroid combination | CD20 (rituximab); DNA (cyclophosphamide); glucocorticoid receptor (dexamethasone) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Alkylating agent + corticosteroid combination class)
- Peking Union Medical College Hospital · 1 drug in this class
- Radboud University Medical Center · 1 drug in this class
- The Cleveland Clinic · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cyclophosphamide and steroids CI watch — RSS
- Cyclophosphamide and steroids CI watch — Atom
- Cyclophosphamide and steroids CI watch — JSON
- Cyclophosphamide and steroids alone — RSS
- Whole Alkylating agent + corticosteroid combination class — RSS
Cite this brief
Drug Landscape (2026). Cyclophosphamide and steroids — Competitive Intelligence Brief. https://druglandscape.com/ci/cyclophosphamide-and-steroids. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing